Cartesian Therapeutics (RNAC) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed Cartesian Therapeutics (RNAC) over the past year, losing 4.1% versus a loss of 31.4%. Entrada Therapeutics is the larger company by market cap ($209.9 million vs $203.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNAC | TRDA |
|---|---|---|
| Share price | $6.71 | $5.39 |
| Market cap | $203.01M | $209.87M |
| 1-day change | +0.45% | -3.92% |
| YTD return | -7.35% | -45.43% |
| 1-year return | -31.42% | -4.10% |
| 5-year return | -94.79% | — |
| EPS (TTM) | $-5.78 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.00 | $16.45 |
| 52-week low | $5.60 | $5.15 |
| Distance from 52-week high | -39.00% | -67.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +401.79% | +252.50% |
| Average volume | 131.99K | 359.01K |
| Shares outstanding | 30.26M | 38.94M |
| Employees | 75 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed RNAC by 27.3 percentage points over the past year.
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
RNAC vs TRDA FAQ
Which is bigger, Cartesian Therapeutics or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $209.87M compared with $203.01M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, RNAC or TRDA?
TRDA returned -4.10% over the past 12 months, compared with -31.42% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Cartesian Therapeutics and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.